Archer Investment Corp Makes New Investment in Liquidia Corporation $LQDA

Archer Investment Corp purchased a new stake in Liquidia Corporation (NASDAQ:LQDA) during the first quarter, Holdings Channel.com reports. The firm purchased 6,859 shares of the company’s stock, valued at approximately $259,000.

Several other large investors have also recently made changes to their positions in LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Liquidia by 10.7% during the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Liquidia by 15.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares in the last quarter. Creative Planning grew its holdings in Liquidia by 40.7% in the second quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after purchasing an additional 7,765 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in Liquidia by 13.4% in the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after purchasing an additional 11,111 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent commentary notes that Liquidia’s Yutrepia has had a strong commercial debut, suggesting early traction in its pulmonary arterial hypertension market opportunity. Can LQDA’s Yutrepia Drive Growth in the Competitive PAH Market?
• Neutral Sentiment: An investor letter from Laughing Water Capital mentioned Liquidia in a broader portfolio update, but did not provide a clear company-specific catalyst. Here’s Laughing Water Capital’s Updates on Liquidia Corp. (LQDA)
• Negative Sentiment: Multiple insiders, including the CEO, CFO, general counsel, and other executives, sold shares on July 13 in pre-arranged 10b5-1 transactions tied to tax withholding from vesting equity awards. While these sales were planned and not necessarily a bearish signal, the size and breadth of the sales may still pressure investor sentiment. SEC filing – Roger Jeffs sale

Analyst Ratings Changes

Several analysts have recently commented on LQDA shares. Needham & Company LLC increased their price objective on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 price target on shares of Liquidia in a research note on Thursday, June 4th. Finally, Wells Fargo & Company raised their price target on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Three investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $68.88.

Liquidia Price Performance

Shares of LQDA opened at $76.49 on Wednesday. The firm has a market capitalization of $6.80 billion, a PE ratio of 546.40 and a beta of 0.55. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. Liquidia Corporation has a 1-year low of $14.04 and a 1-year high of $82.96. The company’s fifty day moving average price is $66.37 and its 200-day moving average price is $47.52.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm’s revenue was up 4187.1% on a year-over-year basis. On average, equities research analysts predict that Liquidia Corporation will post 3.02 EPS for the current year.

Insider Transactions at Liquidia

In related news, Director Stephen M. Bloch sold 318,893 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $50.23, for a total value of $16,017,995.39. Following the sale, the director owned 1,870,042 shares in the company, valued at $93,932,209.66. This represents a 14.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Paul B. Manning sold 200,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $63.91, for a total value of $12,782,000.00. Following the completion of the sale, the director owned 716,311 shares in the company, valued at approximately $45,779,436.01. This represents a 21.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 2,040,973 shares of company stock worth $130,344,087 over the last three months. Corporate insiders own 25.60% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).